Droxinostat

Droxinostat (NS 41080) is a histone deacetylase (HDAC) inhibitor. Droxinostat selectively inhibits HDAC3, HDAC6, and HDAC8 with IC50 values of 16.9 μM, 2.47 μM, and 1.46 μM, respectively. Droxinostat can be used for the research of hepatocellular carcinoma (HCC) [1][2].

Product Specifications

CAS Number

[99873-43-5]

Product Name Alternative

NS 41080

UNSPSC

12352005

Hazard Statement

H302, H315, H318, H335

Target

Apoptosis; HDAC

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Droxinostat.html

Concentration

10mM

Purity

98.91

Solubility

DMSO : ≥ 150 mg/mL

Smiles

ClC1=CC=C(C(C)=C1)OCCCC(NO)=O

Molecular Formula

C11H14ClNO3

Molecular Weight

243.69

Precautions

H302, H315, H318, H335

References & Citations

[1]Liu J, et al. Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP. Transl Oncol. 2016 Feb;9 (1) :70-8.|[2]Wood TE et al. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010 Jan;9 (1) :246-56.